|
|
 |
|
Viewing report
|
|
|
|
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder Chapter
Espicom Business Intelligence Ltd, Nov 2006, Pages: 84
ADHD is now the 9th largest segment of the CNS market by sales with growth of 8% year-on-year. Find out more in this chapter of CNS Drug Discoveries.
The value of the ADHD market was US$2.6 billion in 2005 and it is now the 9th largest segment of the CNS market by sales with growth of 8% year-on-year. Global sales of ADHD drugs are forecast to reach US$4.3 billion by 2012. This will be due to greater penetration in the treatment of new patients, particularly adult ADHD, improvements in patient compliance due to the launch of new formulations, new non-schedule II drugs and the development of novel classes of drugs in late-stage clinical trials.
There has been a significant increase in ADHD diagnosis and prescription of medicine since the early 1990s due to wider understanding of the condition in the mental health community, increased use of medication and healthcare coverage and the launch of ADHD-specific drugs (from 2000 onwards). ADHD is one of the most common psychiatric disorders of childhood and approximately 50% to 70% of children with ADHD will continue to experience symptoms into adulthood. In 2000, it was estimated that 4-5 million individuals (mainly children) were diagnosed with ADHD of whom 75-85% were treated with psychostimulants. Over 8 million adults in the US may exhibit the symptoms of ADHD, while only an estimated 600,000 are being treated.
Global ADHD market
Approximately 90% of ADHD global sales were derived from the US in 2005, with the remainder from Europe. This is largely due to a higher diagnosis rate in paediatrics and availability of drugs for medical reimbursement. Growth in adult ADHD medications has increased exponentially whilst their use in children has slowed due to safety concerns. Growth has also been driven by the launch of new non-stimulant drugs, new patients and the development of new formulations providing flexibility in dosing and higher patient compliance. This has helped to offset the impact of generics which are beginning to emerge on the market.
Key questions answered in this chapter include:
-By what size has the patient population increased in the last 10 years?
-What impact is the treatment of adult ADHD treatment having on the market?
-What strategy is Shire adopting to protect its ADHD franchise from generics?
-What impact has Lilly’s Strattera had on the market?
-What market share has Novartis achieved and how?
-What other companies are entering the ADHD market and how do their products stack up against the competition?
The full report covers 6 key CNS therapy areas; the information provided here is specific to just one chapter. For information on the full report please search our Website. This chapter is available for purchase separately.
Customers who bought this item also bought
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Commercial And Pipeline Insight: ADHD - Immature Adult Market Continues To Offer Greatest Commercial Potential
U.S. Attention Deficit Hyperactivity Disorder (ADHD) Markets
Adult ADHD - Strattera Grows Up
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
The ADD and ADHD Cure: The Natural Way to Treat Hyperactivity and Refocus Your Child
US market size for attention deficit hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, by number of ADHD prescriptions and by dollar value of ADHD pharmaceutical sales; breakout of percent market share, number of prescrip
US market size for attention deficit / hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, number of prescriptions and ADHD drug sales in US dollars for 1999 forecast to 2004, with breakdown of dollar sales, Rx numbers and
Adhd Market: Pestel Analysis and Scenario Based Forecasts
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
Commercial Insight: ADHD - Strattera Reigns Supreme as Branded Stimulants Slump
ADHD & Insomnia Treatments
|
|
|
|
